Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Willingness to comply with study procedures~* Clinical diagnosis of Beta-Thalassemia Intermedia with genotypic confirmation~* Non-transfusion dependent, as defined by: no more than 6 transfusions in the past 12-month period, and no transfusions in the 8-week period prior to Day 1~* Mean Hb within the range of 6.0-10.0 g/dL, inclusive at Screening~* LIC within the range of 3.0-20.0 mg Fe/g dry weight, inclusive~* If using chelators, must be on a stable dose for at least 3 months with LIC \> 5.0 mg Fe/g dry weight and serum ferritin \> 300 nanograms per milliliter (ng/mL)~* Females must be non-pregnant and non-lactating, and either surgically sterile or postmenopausal~* Males must be surgically sterile, abstinent or using an acceptable contraceptive method~Exclusion Criteria:~* Clinically significant abnormalities in lab values, medical history, or physical examination~* α-globin gene triplication~* Symptomatic splenomegaly~* Platelet count \< lower limit of normal (LLN) or \> 1,000 x 10\^9/L~* Significant concurrent/recent coagulopathy, history of non-traumatic significant bleeding; history of immune thrombocytopenic purpura (ITP); current use of SC anti-coagulants; history of thrombotic events, including stroke or DVT~* Clinically significant renal, liver or cardiac dysfunction~* Uncontrolled hypertension (\> 140 mm Hg systolic or \> 90 mm Hg diastolic)~* Fasting blood glucose \> 2.0 × upper limit of normal (ULN)~* Inability to have a magnetic resonance imaging (MRI) scan~* Known history or positive test for human immunodeficiency virus (HIV), hepatitis C (HCV), or hepatitis B (HBV)~* Active infection requiring systemic antiviral or antimicrobial therapy~* Regular excessive use of alcohol~* Recent start of hydroxyurea (6 months prior to Day 1)~* Treatment with or recent exposure to another investigational drug, biological agent, ASO, small interfering ribonucleic acid (siRNA), or device within 1 month of Screening, or 5 half-lives of investigational agent, whichever is longer; or treatment with or exposure to:~  * sotatercept (ACE-011), luspatercept (ACE-536), or ruxolitinib within 4 months of Screening~ * hematopoietic stimulating agents or any hypoxia-inducible factor prolyl hydroxylase inhibitors within 8 weeks of Day 1~ * prior bone marrow transplant, stem cell transplant, or gene therapy~* Surgery associated with significant blood loss within 4 months of Screening, splenectomy within 12 months of Screening, or splenectomy scheduled during treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Sapablursen Dose Level 1 (Cohort A) (Type: EXPERIMENTAL): A single injection of sapablursen at multiple dose levels, administered subcutaneously every 4 weeks.
- Sapablursen Dose Level 1 (Cohort B) (Type: EXPERIMENTAL): A single injection of sapablursen at multiple dose levels, administered subcutaneously every 4 weeks.
- Sapablursen Dose Level 1 (Cohort C) (Type: EXPERIMENTAL): A single injection of sapablursen at multiple dose levels, administered subcutaneously every 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).